Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by…
- Trial name
- FLINT (NCT01265498)
- Testing
- obeticholic acid
- Where
- 9 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NASH - Nonalcoholic Steatohepatitis, Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X…
- Trial name
- NCT03976687
- Testing
- EYP001a
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Iron Depletion Therapy for Type 2 DM and NAFLD
The purpose of this study is to find out whether lowering the amount of iron in the body will result in less resistance to insulin and improved liver function in patients with type 2 diabetes mellitus and non-alcoholic fatty…
- Trial name
- NCT00230087
- Testing
- blood donation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, NASH - Nonalcoholic Steatohepatitis
Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH
The primary objective of this study is to assess efficacy of intragastric balloon for weight loss in obese patients who also concurrently have NASH.
- Conditions
- Obesity, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- NCT03538236
- Testing
- Intragastric balloon, Lifestyle intervention
- Sponsor
- Johns Hopkins University
Non-alcoholic Fatty Liver Disease
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to demonstrate a reduction of intrahepatic fat as measured with Proton Magnetic Resonance Spectroscopy after 12 weeks administration of oral acarbose.
- Trial name
- NCT00677521
- Testing
- Acarbose
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Type2 Diabetes, NAFLD
Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes
The investigators are therefore interested to explore the effects of VLCD and different bariatric surgery procedures to changes in the physical deposition of fat in organs which regulate glucose metabolism (i.e.
- Conditions
- Type2 Diabetes, NAFLD, Obesity
- Trial name
- BARIATRICMRI (NCT05092399)
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Nottingham
Nonalcoholic Fatty Liver Disease
Purified Anthocyanin and Nonalcoholic Fatty Liver Disease
Oxidative stress and inflammation are involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Anthocyanins from different plant foods have been shown to improve features of experimental NASH, such as oxidative…
- Trial name
- NCT01940263
- Testing
- Anthocyanin
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Shaoguan University
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Non-Alcoholic Fatty Liver Disease
Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic and increasing the risk for developing nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01083992
- Testing
- Galvus (vitagliptin), Galvus + vitamin D
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Chronic Hepatitis B, Metabolic Associated Fatty Liver Disease
Analysis of Clinical Characteristics of Chronic Hepatitis B Combined With MAFLD in Different TCM Syndrome Types
This is a retrospective cross-sectional observational clinical study. We will collect clinical medical records of patients diagnosed with chronic hepatitis B combined with metabolic associated fatty liver disease who received…
- Trial name
- NCT07730736
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Obesity, Morbid Obesity
Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery
Surgical management of Morbid Obesity is increasingly frequent. A low-calorie diet is recommended with the main goal of reducing intrahepatic fat infiltration, fat tissue and making easier the surgery.
- Conditions
- Obesity, Morbid Obesity, Bariatric Surgery, Non-alcoholic Fatty Liver
- Trial name
- NCT03849729
- Testing
- Phentermine
- Where
- Mexico
- Volunteers
- 92 people
- Sponsor
- Hospital Juarez de Mexico
Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease
Integrated Approaches for Identifying Molecular Targets in Liver Disease
To provide a framework for successful clinical trials testing novel targets for therapy in liver disease. To identify molecular and cellular drivers of liver disease to provide a molecular classification and study the…
- Conditions
- Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, Steatohepatitis, Nonalcoholic, Steatohepatitis
- Trial name
- InLi (NCT03915002)
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Non-Alcoholic Fatty Liver Disease
Global Osteopathic Treatment for Patients With NAFLD
Non-alcoholic fatty liver disease is a complex disease that is growing more prominent around the world especially in North America because of high prevalence of overweightness and obesity.
- Trial name
- NCT03156881
- Testing
- Global Osteopathic Treatment
- Volunteers
- 48 people
- Sponsor
- Jenna Wilcox
Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Duodenal pulsENDO as an Early Treatment for Type 2 DM
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
- Trial name
- DREAM-1 (NCT07376486)
- Testing
- pulsENDO treatment
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhosis, and validating it with…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05218538
- Testing
- Fibroscan (non interventional)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- HaEmek Medical Center, Israel
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK…
- Trial name
- HI (NCT02891408)
- Testing
- Firsocostat, Fenofibrate
- Where
- 5 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Nonalcoholic Steatohepatitis
A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
Primary objective To investigate the effect of a 24-week, twice daily dosing regimen of ARI-3037MO compared to placebo on plasma triglyceride (TG) levels, liver enzymes and hepatic fat content in patients with dysglycemia and…
- Trial name
- NCT02574325
- Testing
- ARI-3037MO
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Arisaph Pharmaceuticals Inc
Non-alcoholic Fatty Liver Disease, Obesity
Effect of Exercise on Hepatic Fat in Overweight Children
The objective of the present study is to evaluate the effect of 6 months exercise intervention program on hepatic fat fraction in overweight children.
- Conditions
- Non-alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- EFIGRO (NCT02258126)
- Testing
- Multidisciplinary intervention program
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of the Basque Country (UPV/EHU)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.